Corient Private Wealth LP Has $165.01 Million Stock Holdings in Abbott Laboratories $ABT

Key Points

• Corient Private Wealth increased its Abbott Laboratories stake by 9.1% in the second quarter, adding 151,301 shares for a total holding valued at approximately $165.01 million. Institutional investors collectively own 75.18% of Abbott’s stock.
• Analysts remain broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $119.50. Recent firms raised their targets, although UBS lowered its target to $125 while maintaining a buy rating.
• Abbott exceeded quarterly expectations with $1.31 in EPS and $12.59 billion in revenue, up 13% year over year. The company guided for third-quarter 2026 EPS of $1.38–$1.46 and full-year EPS of $5.45–$5.60.

Corient Private Wealth LP increased its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 9.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,818,488 shares of the healthcare product maker's stock after acquiring an additional 151,301 shares during the period. Corient Private Wealth LP owned about 0.11% of Abbott Laboratories worth $165,010,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. California State Teachers Retirement System grew its stake in shares of Abbott Laboratories by 9,127.1% in the 2nd quarter. California State Teachers Retirement System now owns 246,828,861 shares of the healthcare product maker's stock valued at $22,397,251,000 after buying an additional 244,153,804 shares in the last quarter. BlackRock Inc. lifted its stake in Abbott Laboratories by 4.6% in the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker's stock valued at $13,843,610,000 after acquiring an additional 6,769,518 shares during the last quarter. State Street Corp lifted its stake in Abbott Laboratories by 2.1% in the fourth quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker's stock valued at $10,004,880,000 after acquiring an additional 1,627,791 shares during the last quarter. Capital International Investors grew its position in Abbott Laboratories by 2.6% in the fourth quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker's stock worth $7,922,519,000 after acquiring an additional 1,614,706 shares in the last quarter. Finally, J. Stern & Co. LLP increased its stake in shares of Abbott Laboratories by 12,439.6% during the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker's stock worth $4,926,279,000 after purchasing an additional 39,005,451 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ABT. Wells Fargo & Company lifted their price objective on shares of Abbott Laboratories from $109.00 to $112.00 and gave the company an "overweight" rating in a research note on Friday, July 17th. UBS Group lowered their target price on shares of Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating on the stock in a research report on Tuesday, July 28th. JPMorgan Chase & Co. raised their target price on Abbott Laboratories from $110.00 to $120.00 and gave the company an "overweight" rating in a report on Friday, July 17th. BTIG Research boosted their price target on Abbott Laboratories from $131.00 to $134.00 and gave the stock a "buy" rating in a research report on Friday, July 17th. Finally, Royal Bank Of Canada reissued an "outperform" rating and set a $130.00 price objective on shares of Abbott Laboratories in a report on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $119.50.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $102.08 on Friday. The firm has a market capitalization of $176.63 billion, a PE ratio of 33.03, a PEG ratio of 1.92 and a beta of 0.59. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The firm's fifty day simple moving average is $105.60 and its 200 day simple moving average is $99.85.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts' consensus estimates of $1.28 by $0.03. The firm had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business's revenue was up 13.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, sell-side analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Company Profile

Abbott Laboratories NYSE: ABT is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.

The company's medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.